TY  - GEN
AU  - Saab,Sammy
AU  - Gonzalez,Yuri S
AU  - Huber,Caroline
AU  - Wang,Alice
AU  - Juday,Timothy
TI  - Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV
SN  - 1478-3231
PY  - 2016///1221
KW  - 2-Naphthylamine
KW  - Anilides
KW  - economics
KW  - Antiviral Agents
KW  - Carbamates
KW  - Cost-Benefit Analysis
KW  - Cyclopropanes
KW  - Drug Costs
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - drug effects
KW  - Hepatitis C
KW  - diagnosis
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Liver Transplantation
KW  - adverse effects
KW  - Macrocyclic Compounds
KW  - Male
KW  - Markov Chains
KW  - Middle Aged
KW  - Models, Economic
KW  - Phenotype
KW  - Proline
KW  - analogs & derivatives
KW  - Recurrence
KW  - Ribavirin
KW  - Risk Factors
KW  - Ritonavir
KW  - Sulfonamides
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Uracil
KW  - Valine
KW  - Viral Load
KW  - Virus Activation
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/liv.13033
ER  -